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438Objective: Surgical site infection is a major cause of mortality and morbidity. We have explored the use of a mi-
crobial sealant applied before the surgical incision to reduce surgical site infection.
Methods:We conducted a prospective, randomized, controlled clinical trial to determine the efficacy of a cya-
noacrylate sealant in patients undergoing coronary artery bypass grafting. Both left and right long saphenous
veins were harvested in individual patients below the knee if 3 or more lengths of vein were required. The sealant
(Kimberly-Clark InteguSeal, Roswell, Ga) was applied to 1 leg chosen randomly, and the other leg was prepared
in a conventional fashion. Microbiological swabs from the leg wounds were taken at 5 days, and wounds were
assessed according to the Southampton score at 30 days by 2 blinded observers.
Results: The baseline characteristics of the treated and untreated legs were similar because the procedurewas con-
ducted on each individual patient. The studywas terminated at 47 patients after review. Patients in whom the sealant
was usedhad1 (2.1%)wound infection, and therewere12 (25.5%)wound infections in the conventionallyprepared
leg (P¼ .001). Therewere 13 positive cultures from the treated leg and 22 positive cultures from the untreated site.
Conclusions: The microbial skin sealant applied immediately before the incision significantly reduced the rate
of surgical site infection. There was no sensitivity or adverse reaction after application. The treatment was easily
integrated with existing routine preoperative procedures. Microbial sealant may thus be a useful addition to
a multimodal approach to minimize surgical site infection. (J Thorac Cardiovasc Surg 2011;142:438-42)The human body contains 1013 human cells, but also has 1014
resident bacteria. Consequently, any breach in the skin creates
a route for these bacteria to enter the body and potentially
create an infection.1,2 Infection risk is directly proportional
to the dose of bacterial contamination and the virulence of
the organism but inversely proportional to the resistance of
the host. Potential sources of contamination include the
surgical personnel, breaks in sterile technique, operating
room environment, and materials carried into the operating
room. However, a significant alternative source of
pathogens is from the patient’s own skin flora, mucous
membranes, and hollow viscera.
Data from the US Centers for Disease Control National
Nosocomial Infections Surveillance system show that surgi-
cal site infections (SSIs) are the thirdmost frequently reported
nosocomial infections, accounting for 14% to 16% of such
infections among hospitalized patients and 38% among sur-
gical patients.3,4 SSIs impose a substantial clinical burden.e Department of Cardiothoracic Surgery, Fremantle Hospital, Fremantle,
rn Australia, Australia.
ed with the Australian New Zealand Clinical Trials Registry: ACTRN
0007.
res: Authors have nothing to disclose with regard to commercial support.
d for publication Nov 26, 2010; revisions received Jan 12, 2011; accepted for
ation Feb 9, 2011; available ahead of print March 28, 2011.
for reprints: Anand Iyer, MCh, Department of Cardiothoracic Surgery, Fre-
e Hospital, Alma Street, Fremantle, Western Australia: 6160, Australia
il: anandcvts@hotmail.com).
23/$36.00
Copyright  2011 Published by Elsevier Inc. on behalf of The American
tion for Thoracic Surgery
016/j.jtcvs.2011.02.014
The Journal of Thoracic and Cardiovascular SurgPatients with SSIs are more likely to require readmission to
hospital or intensive care unit treatment and are at higher
risk of death than those without such infections. In a case-
controlled study involving 215 matched pairs of patients
with and without SSIs, the relative risk was 2.2 (95% confi-
dence interval [CI], 1.1–4.5) for death associated with SSIs,
5.5 (CI, 4.0–7.7) for readmission, and 1.6 (CI, 1.3–2.0)5 for
intensive care unit treatment. Moreover, patients with SSIs
required longer hospitalization; the median duration of hospi-
talization in infected patients was 11 days, compared with 6
days inuninfectedpatients. Similarly, a reviewof the incidence
and health economic implications of SSIs inEurope found that
the mean length of extended hospitalization was 9.8 days.6
Consequently, SSIs are responsible for a considerable burden
on healthcare costs. In the case-control study described,5 the
median excess cost associatedwith SSIs during a first hospital-
ization was $3089 (95% CI, $2139–4163), and this figure
increased to $5038 in patients who required readmission.5
Similarly, European data suggest that the mean cost of pro-
longed hospitalization due to SSIs is V325 per day.6 Deep
SSIs involving internal organs or body cavities are associated
with even longer hospital stays and further increases in costs,
compared with SSIs that affect only the incision.3
Postoperative SSI is a particularly serious complication
in patients undergoing cardiac surgery. Infected wounds
usually require prolonged therapy and hospitalization. Ster-
nal wound complications result in increased morbidity and
mortality, reaching 10% to 40%.7-9
Efforts to reduce the rate of SSI in all types of surgery have
been directed at modifying risk factors. Procedures focusedery c August 2011
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CI ¼ confidence interval
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Mon reducing bacterial contamination of the surgical site,
administering appropriate antibiotic prophylaxis, and using
meticulous surgical technique.10 Scrubbing of the operative
site with a variety of antiseptic solutions before surgery has
been studied, and although this substantially reduces the
skin flora, approximately 20% of the microbes remain
buried deep in hair follicles and sweat glands and persist af-
ter scrubbing.11 Thus, complete sterilization of the skin is
not possible. The use of a microbial sealant in the prepara-
tion of a patient for surgery is a recent technologic develop-
ment with the potential to reduce rates of SSI. The sealant
forms a breathable barrier that prevents migration of skin
flora into the incision. In contrast with conventional skin
preparations, the sealant also seals microabrasions on the
skin, thus preventing recolonization of such spaces with re-
sidual potential pathogens after skin sterilization. Because
the sealant physically locks down the pathogens, there is
no potential for the development of microbial antibiotic re-
sistance. This article reports the effect of pretreatment with
n-butyl cyanoacrylate-based microbial skin sealant in a pop-
ulation undergoing cardiac surgery and discusses its poten-
tial use in decreasing infections in other kinds of surgical
procedures.
MATERIALS AND METHODS
Study Population
We began the trial in August 2008 after the research was approved by
the institutional ethics committee registered with the Australian New Zea-
land Clinical Trials Registry. Forty-seven patients were studied; recruit-
ment was halted at this number after further ethical committee review.
Patient follow-up was complete at 1 month. Patients were eligible for inclu-
sion in the study if undergoing coronary artery bypass graft (CABG) sur-
gery and requiring 3 or more lengths of long saphenous vein to achieve
revascularization. Additional internal thoracic conduit was also routinely
used. The long saphenous vein grafts were taken from the below-knee seg-
ment in both legs of all patients. The sealant was applied to only 1 leg per
case, selected randomly. The other leg thus acted as a matched control. The
sealant was not used on the sternal incision. All patients gave written in-
formed consent. Major exclusion criteria were if the patient required 2
segments of vein wherein only 1 leg would be used and any features that
would cause dissimilarity between the legs, which included the vein in ei-
ther leg not being usable, unilateral vascular disease, or skin lesion. Patients
were also excluded if there was a discrepancy in length of the skin incision
between the treated and untreated legs. By comparing 1 leg with the other,
any bias with regard to patient characteristics was avoided. Patient charac-
teristics are shown in Table 1.
Surgical Technique
Apart from the application of the sealant to the treated leg, surgical tech-
niques for both legs were identical. Hair removal was performed using anThe Journal of Thoracic and Caelectrical clipper the day before surgery. Patients then washed by soap on
the morning of surgery. The skin was disinfected using alcoholic povidone-
iodine solution, and 3 minutes were allowed for the disinfecting solution to
dry before the application of microbial sealant. The microbial sealant was
applied to one of the legs on a random basis. No sham application was used
in the untreated leg. The InteguSeal IS 100 (Kimberly-Clark, Roswell, Ga)
applicator was used to apply a single, even layer of microbial sealant over
an area overlying the saphenous vein harvest site. The cost of 1 applicator
was A$30, which was paid by the hospital. Another delay of 2 minutes
allowed the sealant to dry. Iodine-impregnated drapes were used in all
patients (Ioban; 3M, St Paul, Minn). Veins were harvested by a single
open incision. Endoscopic techniques were not adopted, and in most of
the patients the below portion of veins was harvested. Standard surgical
procedure involved closure of subcutaneous layer with 2-0 Vicryl (Covi-
dien, Mansfield, Mass/US Surgical, Norwalk, Conn) and subcuticular
closure of the skin with 3-0 Caprosyn (Covidien/US Surgical). A hydrocol-
loid dressing, Comfeel (Coloplast, Humlebaek, Denmark) was used in all
patients. All patients underwent cardiopulmonary bypass with systemic
cooling to 32C to 34C. All patients underwent standard bypass grafts.
None of the patients in the study had perioperative infarctions, and there
were no adverse intraoperative events. There was no correlation of infec-
tion with the bypass time. The incisions were approximately the same
length in both legs in most of the patients, but this had no bearing in causing
infections.
Study Outcomes
The wounds of all the patients were examined daily during the postop-
erative stay, and a wound swab was taken from both legs on the fourth post-
operative day. If there was infection, the swabs were taken from that
particular region. If there was no infection, a culture swab was applied to
a segment of skin incision. The bacterial isolates obtained from the wounds
of all patients along the incision site before their discharge were identified
using routine microbiological diagnostic procedures. Preoperative swabs
were not taken. If the wound was showing signs of infection, it was graded
per the Southamptonwound grading system.12 Findingswere recorded, and
the wound infection was managed accordingly. All patients were followed
up by 1 of 2 blinded observers (who were registrars in the unit) at 4 weeks
postdischargewhen thewounds were examined. Findings were recorded. If
a general practitioner involved with the care after discharge detected an in-
fection before the 4-week follow-up, an appointment was arranged before
the stipulated follow-up and the findings were recorded.
TheSouthampton score divideswounds into5grades: 0¼ normalhealing;
grade 1¼ normal healingwith bruising or erythema, subclassified asA, B, or
C according to the size of bruising; grade 2 ¼ erythema with other signs of
inflammation, subclassified as A, B, or C according to findings at 1 point,
around the sutures, or around the whole wound; grade 3¼ haemoserous dis-
charge (A< 2 cm, B> 2 cm, C ¼ large volume, D> 3 days); grade
4¼ purulent discharge (A<2 cm, B>2 cm); and grade 5¼ deep or severe
infection with or without tissue breakdown.12
Statistical Analysis
The study design was a prospective, randomized, double-blind trial, and
variables were analyzed using the z test.RESULTS
Forty-seven patients (ie, 94 legs) were enrolled. In the
sealant group, 1 leg developed a severe infection and re-
quired incision and drainage, and Staphylococcus aureus
was isolated. In the same patient, the untreated leg had no
infection. In the remaining 46 treated legs, there was no
infection observed at 30 days. We are not aware of any in-
fection developing beyond this point. In the 46 uninfectedrdiovascular Surgery c Volume 142, Number 2 439
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FIGURE 1. Wound infection in sealant and control groups.
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Mtreated legs, 12 (26.08%) grew organisms on culture, the
majority of which were skin flora and S epidermidis.
Twelve legs in the untreated group showed evidence of
infection that ranged from oozing of serous fluid, which re-
sponded to conservative therapy, to severely infected wound
requiring debridement (Figure 1). Four patients required in-
cision and drainage, and 1 patient required a debridement.
Of the remaining 35 healed legs, 14 (40%) had a positive
culture. None of the infected patients had long-term conse-
quences (Table 2).
Statistical Analysis
Group 1 (sealant) included 47 patients, and group 2 (no
sealant) included 47 patients (P¼ .001l; 95% CI for differ-
ence,0.374 to0.0945). There was a significant difference
in the proportions of individuals with infection within the 2
groups.
DISCUSSION
In cardiac surgery, sternal wound infection continues to
be one of the most serious postoperative complications.13
Coagulase-negative staphylococci have become the most
common causative agents of sternal wound infection, fol-
lowed by S aureus and others, such as the gram-negative
rods.13,14 Although the frequency of sternal infection is
reported to be low, between 0.7% and 3.3%, the costs
associated with multiple procedures and increased
hospital stay should not be underestimated.15,16 SSIs inTABLE 1. Patient characteristics
Age (y), mean (SD) 67.0 (7.6)
Male 39 (82.9%)
Female 8 (17.02%)
Hyperlipidemia 40 (85.1%)
Arterial hypertension 31 (65.9%)
Diabetes mellitus 12 (25.5%)
Peripheral vascular disease 0 (0)
Renal failure 4 (8.5%)
Ejection fraction, mean (SD) 47.3 (13.3)
Venous disease in the leg 0
SD, Standard deviation.
440 The Journal of Thoracic and Cardiovascular Surgany specialty have their own implications with regard to
patient morbidity and mortality, hospital stay, and cost. It
was estimated that there are 175,153 (95% credible
interval, 155,911:195,168) cases of healthcare-acquired in-
fection among admissions to Australian hospitals annually,
and the extra stay in the hospital to treat symptoms accounts
for 854,289 bed days (95% credible interval, 645,091:
1,096,244). If rates were reduced by 1%, then 150,158
bed days would be released for alternative uses.17 On the
basis of the findings of a Victorian Nosocomial Infection
Surveillance System (VICNISS) study18 investigating the
impact of hospital-acquired infections on the health system,
the 225 SSIs reported between July 2005 and June 2008 in
Western Australia are estimated to have cost A$8.1 million
and consumed 5800 additional bed days.18
We performed this trial in leg wounds. Leg wound com-
plications have been reported to occur in 2% to 24% of
cases19,20 and has been as high as 42.8% in one series.21
The incidence of wound infection in the leg has been 12
of 47 cases in the untreated legs because the criteria accord-
ing to Southampton score is stringent, and even minimal er-
ythema or discharge has been included as infection. We
have followed patients for 1 month after discharge and
reviewed them before if there were any doubts raised about
infection by the general practitioner and even minimal
erythema or small discharge in the wounds were considered
infections. Some patients were discharged without any is-
sues and during the follow-up were noted to have signs of
infection. Although postdischarge follow-up is good in
many centers, there is a likelihood that such events may
be managed exclusively by the practitioner without referral
to the primary unit if not specified in the discharge note. The
ability to track events that occur and are managed on an out-
patient basis may be less reliable,22 and the true incidence
of leg infections may be underreported.
The trial wasrandomized without bias because 1 leg in
the same patient was compared with the other. We also
used the below-knee portion of the vein in most of the
patients for grafting becausewe have encountered increased
wound infections in the thigh region. According to
Akowuah and colleagues,23 the ASEPSIS score (Additional
treatment, Serous discharge, Erythema, Purulent exudates,
Separation of deep tissues, Isolation of bacteria, Stay in hos-
pital prolonged over 14 days) is reduced when vein harvest
is restricted to below the level of the knee. This study found
that the use of a microbial sealant before incision signifi-
cantly reduced the rate of leg wound infections among
patients undergoing CABG.
The risk of SSI is considered elevated when the level of
contamination is high, although lower doses may be required
if foreign material, such as sutures, is present.3 In an in
vitro skin incision model, recovery of methicillin-resistant
S aureus was reduced by 99.9% with the sealant, whereas
the recoveries of S epidermidis and Escherichia coli wereery c August 2011
TABLE 2. Wound infections and cultures in the study population (with and without microbial sealant)
Infection graded per Southampton score
(isolated organism) No infection (isolated organism)
Microbial sealant 1. Grade 4B Staphylococcus aureus 34 no growth
4 skin flora
4 coagulase-negative
Staphylococcus
1 Enterococcus
1 Klebsiella
1 coliform
1 Enterobacter (light growth)
Untreated legs 1. Grade 3D S aureusþcoliforms
2. Grade 5 Escherichia coli
3. Grade 5 S aureus
4. Grade 4B KlebsiellaþE coli
5. Grade 3D skin flora
6. Grade 3B no growth
7. Grade 5 skin flora
8. Grade 3A no growth
9. Grade 3B Serratia marcescens
10. Grade 3B S epidermidis
11. Grade 3B S epidermidis
12. Grade 4B Enterobacter aerogenes
22 no growth
9 coagulase-negative
Staphylococcus
2 skin flora
1 Klebsiella
1 coliform
Iyer et al Perioperative Managementreduced by 99.5% and 96.6%, respectively.24 In another
study, the microbial sealant reduced the recovery of
drug-resistant Acinetobacter baumannii by a factor of 101.5.
A baumannii is another pathogen that has been implicated
in SSIs in patients receiving antimicrobial prophylaxis.5
SSIs impose a substantial burden of mortality and mor-
bidity, which increase the demands on resources. This study
lends evidence toward implementing sealants into routine
clinical practice as being appropriate and supports the find-
ings of Dohmen and colleagues,25 who showed that sealants
significantly reduced sternal wound infection rates.
Cyanoacrylate may act as a skin irritant and cause an al-
lergic skin reaction, but we have found no reports of toxicity
or allergies to butyl cyanoacrylate, which is being used as
the sealant.P
MCONCLUSIONS
The use of a microbial skin sealant before surgery re-
duced the rate of SSI among patients undergoing CABG.
There were no cases of skin sensitivity or other reaction af-
ter application of the microbial sealant, which can be used
with a variety of skin preparation solutions and most wound
closure techniques. The pretreatment is straightforward and
has been easily integrated with existing routine preoperative
procedures at this surgical center. Microbial sealant may
thus be a useful addition to the multimodal approach to min-
imize bacterial contamination of surgical incisions, which is
key in SSI prevention. It is likely that these outcomes can be
reproduced in other clean surgical procedures.The Journal of Thoracic and CaThe authors thank Leon Neethling (research officer) for per-
forming the statistical analysis of the data.
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